Thursday, July 20, 2023
SCG Cell Therapy has announced the opening of its Cell Therapy cGMP Manufacturing Facility and R&D Centre in Singapore.
The state-of-the-art facility builds upon SCG's expertise in advanced cell therapy manufacturing and human-induced Pluripotent Stem Cell (iPSC) technology, offering great promise for the region's medical landscape.
This new facility enables to supply cell therapy products to partner hospitals across Asia Pacific, North America, and Europe, enhancing accessibility to cutting-edge treatments worldwide. This development aligns with Singapore's advanced manufacturing initiatives, signifying a major step forward in cell therapy manufacturing within the region.
The opening of the R&D centre also represents a significant step for SCG Cell Therapy. This facility will play a pivotal role in supporting the research of its pipeline of cell therapy product candidates, aligning with the Singaporean government's vision to establish the country as a global innovation hub.
